Antidepressant-like effect of creatine in mice involves dopaminergic activation

Journal of Psychopharmacology

Volumn 26, Issue 11, 2012, Pages 1489-1501

  Cunha, Mauricio P ^a   MacHado, Daniele G ^a   Capra, Juliano C ^a   Jacinto, Jardel ^a   Bettio, Luis E B ^a   Rodrigues, Ana Lúcia S ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Antidepressant; creatine; dopaminergic system; tail suspension test

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; AMFEBUTAMONE; APOMORPHINE; CREATINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR;

ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; MALE; MOUSE; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; RECEPTOR UPREGULATION;

ANIMALS; ANTIDEPRESSIVE AGENTS; CREATINE; DEPRESSION; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MALE; MICE; MOTOR ACTIVITY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2;

EID: 84867503767     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881112447989     Document Type: Article

References (66)

1. Allen PJ, D'Anci KE, Kanarek RB, et al. Chronic creatine supplementation alters depression-like behavior in rodents in a sex-dependent manner. Neuropsychopharmacology. 2010 ; 35: 534-546
2. Amital D, Vishne T, Roitman S, et al. Open study of creatine monohydrate in treatment-resistant posttraumatic stress disorder. J Clin Psychiatry. 2006 ; 67: 836-837
3. Andres RH, Ducray AD, Schlattner U, et al. Functions and effects of creatine in the central nervous system. Brain Res Bull. 2008 ; 76: 329-343
4. Andres RH, Huber AW, Schlattner U, et al. Effects of creatine treatment on the survival of dopaminergic neurons in cultured fetal ventral mesencephalic tissue. Neuroscience. 2005 ; 133: 701-713
5. Assis LC, Rezin GT, Comim CM, et al. Effect of acute administration of ketamine and imipramine on creatine kinase activity in the brain of rats. Rev Bras Psiquiatr. 2009 ; 31: 247-252
6. Becker C, Brobert GP, Johansson S, et al. Risk of incident depression in patients with Parkinson disease in the UK. Eur J Neurol. 2010 ; 18: 448-453
7. Bender A, Koch W, Elstner M, et al. Creatine supplementation in Parkinson disease: A placebo-controlled randomized pilot trial. Neurology. 2006 ; 67: 1262-1264
8. Berton O, Nestler EJ. New approaches to antidepressant drug discovery: Beyond monoamines. Nature Rev Neurosci. 2006 ; 7: 137-151
9. Binfaré RW, Mantovani M, Budni J, et al. Involvement of dopamine receptors in the antidepressant-like effect of melatonin in the tail suspension test. Eur J Pharmacol. 2010 ; 638: 78-83
10. Borsini F, Meli A. Is the forced swimming test a suitable model for revealing antidepressant activity?. Psychopharmacology. 1988 ; 94: 147-160
11. Borsini F, Lecci A, Sessarego A, et al. Discovery of antidepressant activity by forced swimming test may depend on pre-exposure of rats to a stressful situation. Psychopharmacology. 1989 ; 97: 183-188
12. Burroughs S, French D. Depression and anxiety: Role of mitochondria. Curr Anaesth Crit Care. 2007 ; 18: 34-41
13. Capra JC, Cunha MP, Machado DG, et al. Antidepressant-like effect of scopoletin, a coumarin isolated from Polygala sabulosa (Polygalaceae) in mice: Evidence for the involvement of monoaminergic systems. Eur J Pharmacol. 2010 ; 643: 232-238
14. Cardoso CC, Lobato KR, Binfaré RW, et al. Evidence for the involvement of the monoaminergic system in the antidepressant-like effect of magnesium. Prog Neuropsychopharmacol Biol Psychiatry. 2009 ; 33: 235-242
15. Christensen AV, Arnt J, Hyttel J, et al. Pharmacological effects of a specific dopamine D1 antagonist SCH23390 in comparison with neuroleptics. Life Sci. 1984 ; 34: 1529-1540
16. Clausius N, Born C, Grunze H. The relevance of dopamine agonists in the treatment of depression. Neuropsychiatry. 2009 ; 23: 15-25
17. Cooper BR, Hester TJ, Maxwell RA. Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): Evidence for selective blockade of dopamine uptake in vivo. J Pharmacol Exp Ther. 1980 ; 215: 127-134
18. Cryan JF, Mombereau C, Vassout A. The tail suspension test as a model for assessing antidepressant activity: Review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev. 2005 ; 29: 571-625
19. Cunha MP, Machado DG, Bettio LEB, et al. Interaction of zinc with antidepressants in the tail suspension test. Prog Neuropsychopharmacol Biol Psychiatry. 2008 ; 32: 1913-1920
20. Dager SR, Friedman SD, Parow A. Brain metabolic alterations in medication-free patients with bipolar disorder. Arch Gen Psychiatry. 2004 ; 61: 450-458
21. D'Aquila PS, Collu M, Gessa GL, et al. The role of dopamine in the mechanism of action of antidepressants drugs. Eur J Pharmacol. 2000 ; 405: 365-373
22. D'Aquila PS, Collu M, Pani L, et al. Antidepressant-like effect of selective dopamine D1 receptor agonists in the behavioural despair animal model of depression. Eur J Pharmacol. 1994 ; 262: 107-111
23. Freitas AE, Budni J, Lobato KR, et al. Antidepressant-like action of the ethanolic extract from Tabebuia avellanedae in mice: Evidence for the involvement of the monoaminergic system. Prog Neuropsychopharmacol Biol Psychiatry. 2010 ; 34: 335-343
24. Gambarana C, Ghiglieri O, Tagliamonte A, et al. Crucial role of D1 dopamine receptors in mediating the antidepressant effect of imipramine. Pharmacol Biochem Behav. 1995 ; 50: 147-151
25. Garattini S. Pharmacology of amineptine, an antidepressant agent acting on the dopaminergic system: A review. Int Clin Psychopharmacol. 1997 ; 12: S15 - S19
26. Hyttel J. Functional evidence for selective dopamine D-1 receptor blockade by SCH23390. Neuropharmacology. 1984 ; 23: 1395-1401
27. Holtzheimer PE, Nemeroff CB. Advances in the treatment of depression. J NeuroRx. 2006 ; 3: 42-56
28. Inoue T, Tsuchiya K, Miura J, et al. Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression. Biol Psychiatry. 1996 ; 40: 151-153
29. Kato T, Takahashi S, Shioiri T, et al. Brain phosphorous metabolism in depressive disorders detected by phosphorus-31 magnetic resonance spectroscopy. J Affect Disord. 1992 ; 26: 223-230
30. Ketter TA, Kimbrell TA, George MS, et al. Effects of mood and subtype on cerebral glucose metabolism in treatment-resistant bipolar disorder. Biol Psychiatry. 2001 ; 49: 97-109
31. Kim SY, Lee YJ, Kim H, et al. Desipramine attenuates forced swim test-induced behavioral and neurochemical alterations in mice: An in vivo(1)H-MRS study at 9.4T. Brain Res. 2010 ; 1348: 105-113
32. Kulkarni SK, Bhutani MK, Bishnoi M. Antidepressant activity of curcumin: Involvement of serotonin and dopamine system. Psychopharmacology. 2008 ; 201: 435-442
33. Leuchter AF, Cook IA, Gilmer WS, et al. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder. Psychiatry Res. 2009 ; 169: 132-138
34. Machado DG, Bettio LEB, Cunha MP, et al. Antidepressant-like effect of the extract of Rosmarinus of cinalis in mice: Involvement of the monoaminergic system. Prog Neuropsychopharmacol Biol Psychiatry. 2009 ; 33: 642-650
35. Machado DG, Kaster MP, Binfaré RW, et al. Antidepressant-like effect of the extract from leaves of Schinus molle L. in mice: Evidence for the involvement of the monoaminergic system. Prog Neuropsychopharmacol Biol Psychiatry. 2007 ; 31: 421-428
36. McMorris T, Harris RC, Swain J, et al. Effect of creatine supplementation and sleep deprivation, with mild exercise, on cognitive and psychomotor performance, mood state, and plasma concentrations of catecholamines and cortisol. Psychopharmacology. 2006 ; 186: 93-103
37. Matsumoto K, Cai B, Ohta H, et al. Apparent enhancement by SCH23390 of apomorphine-induced locomotor activity in mice. Pharmacol Biochem Behav. 1991 ; 39: 699-703
38. Matthews RT, Ferrante RJ, Klivenyi P, et al. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol. 1999 ; 157: 142-149
39. Melo FH, Moura BA, de Sousa DP, et al. Antidepressant-like effect of carvacrol (5-Isopropyl-2-methylphenol) in mice: Involvement of dopaminergic system. Fundam Clin Pharmacol. 2011 ; 25: 362-367
40. Millan MJ, Maiofiss L, Cussac D, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002 ; 303: 791-804
41. Missale C, Nash SR, Robinson SW, et al. Dopamine receptors: From structure to function. Physiol Rev. 1998 ; 78: 189-225
42. Mitani H, Shirayama Y, Yamada T, et al. Plasma levels of homovanillic acid, 5-hydroxyindoleacetic acid and cortisol, and serotonin turnover in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry. 2006 ; 30: 531-534
43. Moore CM, Christensen JD, Lafer B, et al. Lower levels of nucleoside triphosphate in the basal ganglia of depressed subjects: A phosphorous-31 magnetic resonance spectroscopy study. Am J Psychiatry. 1997 ; 154: 116-118
44. Moretti A, Gorini A, Villa RF. Affective disorders, antidepressant drugs and brain metabolism. Mol Psychiatry. 2003 ; 8: 773-785
45. Nemeroff CB, Owens MJ. Treatment of mood disorders. Nature Neurosci. 2002 ; 5: 1068-1070
46. Nestler EJ, Carlezon WA. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry. 2006 ; 59: 1151-1159
47. Nikulina EM, Skrinskaya JA, Popova NK. Role of genotype and dopamine receptors in behaviour of inbred mice in a forced swimming test. Psychopharmacology. 1991 ; 105: 525-529
48. Ongür D, Prescot AP, Jensen JE, et al. Creatine abnormalities in schizophrenia and bipolar disorder. Psychiatry Res. 2009 ; 172: 44-48
49. Papakostas GI. Evidence for S-adenosyl-L-methionine (SAM-e) for the treatment of major depressive disorder. J Clin Psychiatry. 2009 ; 70: 18-22
50. Renard CE, Fiocco AJ, Clenet F, et al. Is dopamine implicated in the antidepressant-like effects of selective serotonin reuptake inhibitors in the mouse forced swimming test?. Psychopharmacology. 2001 ; 159: 42-50
51. Richelson E. Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance. J Clin Psychiatry. 2003 ; 64: 5-12
52. Roitman S, Green T, Osher Y, et al. Creatine monohydrate in resistant depression: A preliminary study. Bipolar Disord. 2007 ; 9: 754-758
53. Salmi P, Malmgren K, Svensson TH, et al. Stimulation of forward locomotion by SCH-23390 and raclopride in d-amphetamine-treated rats. Naunyn Schmiedebergs Arch Pharmacol. 1998 ; 357: 593-599
54. Sher L, Mann JJ, Traskman-Bendz L, et al. Lower cerebrospinal fluid homovanillic acid levels in depressed suicide attempters. J Affect Disord. 2006 ; 90: 83-89
55. Shimazu S, Minami A, Kusumoto H, et al. Antidepressant-like effects of selegiline in the forced swim test. Eur Neuropsychopharmacol. 2005 ; 15: 563-571
56. Siris SG. Depression in schizophrenia: Perspective in the era of 'Atypical' antipsychotic agents. Am J Psychiatry. 2000 ; 157: 1379-1389
57. Siuciak JA, Fujiwara RA. The activity of pramipexole in the mouse forced swim test is mediated by D2 rather than D3 receptors. Psychopharmacology. 2004 ; 175: 163-169
58. Steru L, Chermat R, Thierry B, et al. The tail suspension test: A new method for screening antidepressants in mice. Psychopharmacology. 1985 ; 85: 367-370
59. Stoof JC, Kebabian JW. Two dopamine receptors: Biochemistry, physiology and pharmacology. Life Sci. 1984 ; 35: 2281-2296
60. Teste JF, Martin I, Rinjard P. Electrotherapy in mice: Dopaminergic and noradrenergic effects in the tail suspension test. Fundam Clin Pharmacol. 1990 ; 4: 39-47
61. Teste JF, Pelsy-Johann I, Decelle T, et al. Anti-immobility activity of different antidepressant drugs using the tail suspension test in normal or reserpinized mice. Fundam Clin Pharmacol. 1993 ; 7: 219-226
62. Vamvakidès A. Effect of presynaptic dopaminergic agonism on the immobility of mice in the forced swimming test. Ann Pharm Fr. 1999 ; 57: 374-379
63. Wong ML, Licinio J. Research and treatment approaches to depression. Nature Rev Neurosci. 2001 ; 2: 343-351
64. Volz HP, Rzanny R, Riehemann S, et al. Eur Arch Psychiatry Clin Neurosci. 1998 ; 248: 289-295
65. Yamada J, Sugimoto Y, Yamada S. Involvement of dopamine receptors in the anti-immobility effects of dopamine re-uptake inhibitors in the forced swimming test. Eur J Pharmacol. 2004 ; 504: 207-211
66. Zarrindast MR, Moghaddampour E. Opposing influences of D-1 and D-2 dopamine receptors activation on morphine-induced antinociception. Arch Int Pharmacodyn Ther. 1989 ; 300: 37-50